A recent report from a federal watchdog agency seeks to clarify what gain-of-function research means and pushes for ...
Attorney General Rob Bonta announced the agreement Tuesday, a day after a state court unsealed a whistleblower complaint ...
In the first full legislative session after Roe v. Wade was overturned, states across the country are looking to further ...
Jonas, who has type 1 diabetes and has been a paid spokesperson for Dexcom since 2015, will headline its Super Bowl ...
The number of children — especially very young ones — ingesting marijuana is rising in Colorado despite regulations meant to ...
Sermo has acquired Payer Access and Charter Oak as part of its effort to boost its payer and oncologist reach, the company ...
During an interview with KHN at his Senate office recently, the independent from Vermont spoke about the prospects for ...
Biden outlined the implications of the Inflation Reduction Act on both consumers and the pharmaceutical industry, as well as ...
The rules of the past no longer apply after the seismic events of the past three years. To reflect that, HCB Health has ...
The insurance giant considers Relyvrio to be “experimental, investigational or unproven” for any use. Cigna won’t cover Amylyx Pharmaceutical’s amyotrophic lateral sclerosis (ALS) drug Relyvrio, ...
It was closing 36 of the 71 branches of its Coram home infusion business and laying off about 2,000 nurses, dietitians, ...
Eisai announced a trio of firsts yesterday, yet significant sales of Leqembi depend on more clarity around Medicare ...